InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Depreciation & Amortization (CF) of $50509.0 for Q1 2026, down 3.43% year-over-year from $52305.0 in Q1 2025, and down 5.06% quarter-over-quarter from $53201.0 in Q4 2025.
InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $50509.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 3.43% year-over-year to $50509.0; the TTM figure through Mar 2026 stood at $209664.0 (down 2.42% YoY), while the FY2025 annual figure was $212839.0, down 3.08% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $50509.0, down from $53201.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $55231.0 in Q4 2023, with the low at $49048.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $53203.0 (2024), against an average of $52878.1.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 94.52% in 2022, then decreased 4.97% in 2023.
- InMed Pharmaceuticals' Depreciation & Amortization (CF) stood at $49049.0 in 2022, then grew by 12.6% to $55231.0 in 2023, then retreated by 3.67% to $53203.0 in 2024, then dropped by 0.0% to $53201.0 in 2025, then declined by 5.06% to $50509.0 in 2026.
- Business Quant data shows INM's Depreciation & Amortization (CF) at $50509.0 in Q1 2026, $53201.0 in Q4 2025, and $53202.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | 50,509.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,509.00 |
| Mar 31, 2026 | 50,509.00 |
| Dec 31, 2025 | 53,201.00 |
| Dec 31, 2025 | 53,201.00 |
| Sep 30, 2025 | 53,202.00 |
| Sep 30, 2025 | 53,202.00 |
| Jun 30, 2025 | 52,752.00 |
| Jun 30, 2025 | 52,752.00 |
| Mar 31, 2025 | 52,305.00 |
| Mar 31, 2025 | 52,305.00 |
| Dec 31, 2024 | 53,203.00 |
| Dec 31, 2024 | 53,203.00 |
| Sep 30, 2024 | 54,579.00 |
| Sep 30, 2024 | 54,579.00 |
| Jun 30, 2024 | 54,767.00 |
| Jun 30, 2024 | 54,767.00 |
| Mar 31, 2024 | 54,770.00 |
| Mar 31, 2024 | 54,770.00 |
| Dec 31, 2023 | 55,231.00 |
| Dec 31, 2023 | 55,231.00 |